Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
Jiang Q, Stachelscheid J, Bloehdorn J, Pacholewska A, Aszyk C, Grotenhuijs F, Müller T, Onder O, Wagle P, Herling CD, Kleppe M, Wang Z, Coombes KR, Robrecht S, Dalvi PS, Plosnita B, Mayer P, Abruzzo LV, Altmüller J, Gathof B, Persigehl T, Fischer K, Jebaraj B, Rienhoff HY, Ecker R, Zhao Y, Bruns CJ, Stilgenbauer S, Elenitoba-Johnson K, Hallek M, Schweiger MR, Odenthal M, Vasyutina E, Herling M. Jiang Q, et al. Among authors: jebaraj b. Blood. 2023 Jul 6;142(1):44-61. doi: 10.1182/blood.2022017230. Blood. 2023. PMID: 37023372
Telomere Dysfunction in Chronic Lymphocytic Leukemia.
Jebaraj BMC, Stilgenbauer S. Jebaraj BMC, et al. Front Oncol. 2021 Jan 15;10:612665. doi: 10.3389/fonc.2020.612665. eCollection 2020. Front Oncol. 2021. PMID: 33520723 Free PMC article. Review.
IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S. Scheffold A, et al. Blood. 2019 Aug 8;134(6):534-547. doi: 10.1182/blood.2018881029. Epub 2019 Apr 22. Blood. 2019. PMID: 31010847 Free PMC article.
Telomere length in mantle cell lymphoma.
Jebaraj BM, Kienle D, Lechel A, Mertens D, Heuberger M, Ott G, Rosenwald A, Barth TF, Möller P, Zenz T, Döhner H, Stilgenbauer S. Jebaraj BM, et al. Blood. 2013 Feb 14;121(7):1184-7. doi: 10.1182/blood-2012-08-452649. Epub 2012 Dec 14. Blood. 2013. PMID: 23243283 Free article.
BRAF mutations in chronic lymphocytic leukemia.
Jebaraj BM, Kienle D, Bühler A, Winkler D, Döhner H, Stilgenbauer S, Zenz T. Jebaraj BM, et al. Leuk Lymphoma. 2013 Jun;54(6):1177-82. doi: 10.3109/10428194.2012.742525. Epub 2012 Nov 20. Leuk Lymphoma. 2013. PMID: 23088640
Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
Steinbrecher D, Jebaraj BMC, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S. Steinbrecher D, et al. Leuk Lymphoma. 2018 Jul;59(7):1614-1623. doi: 10.1080/10428194.2017.1390236. Epub 2017 Oct 24. Leuk Lymphoma. 2018. PMID: 29063805 Clinical Trial.
Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.
Jebaraj BMC, Tausch E, Landau DA, Bahlo J, Robrecht S, Taylor-Weiner AN, Bloehdorn J, Scheffold A, Mertens D, Böttcher S, Kneba M, Jäger U, Zenz T, Wenger MK, Fingerle-Rowson G, Wendtner C, Fink AM, Wu CJ, Eichhorst B, Fischer K, Hallek M, Döhner H, Stilgenbauer S. Jebaraj BMC, et al. Leukemia. 2019 Sep;33(9):2183-2194. doi: 10.1038/s41375-019-0446-4. Epub 2019 Mar 25. Leukemia. 2019. PMID: 30911113 Free PMC article. Clinical Trial.
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.
Bloehdorn J, Krzykalla J, Holzmann K, Gerhardinger A, Jebaraj BMC, Bahlo J, Humphrey K, Tausch E, Robrecht S, Mertens D, Schneider C, Fischer K, Hallek M, Döhner H, Benner A, Stilgenbauer S. Bloehdorn J, et al. Haematologica. 2022 Mar 1;107(3):615-624. doi: 10.3324/haematol.2020.251561. Haematologica. 2022. PMID: 33730841 Free PMC article.
Venetoclax: Targeting BCL2 in Hematological Cancers.
Scheffold A, Jebaraj BMC, Stilgenbauer S. Scheffold A, et al. Recent Results Cancer Res. 2018;212:215-242. doi: 10.1007/978-3-319-91439-8_11. Recent Results Cancer Res. 2018. PMID: 30069633 Review.
29 results